Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyDevelopment of cell-cycle checkpoint therapy for solid tumorsChemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingStructure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesCell cycle checkpoint in cancer: a therapeutically targetable double-edged swordThe cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial designHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Development of synthetic lethality anticancer therapeutics.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphomaPhase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumorsDistinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S PhaseIn vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemiaAZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repairThe Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.Cell cycle proteins as promising targets in cancer therapyTherapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms.Emerging cell cycle inhibitors for acute myeloid leukemia.Targeting the ATR-CHK1 Axis in Cancer TherapyTargeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer CellsCell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitorThe combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.Studies of lncRNAs in DNA double strand break repair: what is new?ATR/CHK1 inhibitors and cancer therapy.Directing the use of DDR kinase inhibitors in cancer treatment.Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
P2860
Q26745686-41DD8F50-7C1C-45A6-A192-5238662D5FE0Q26781187-D267ABAE-9EB0-47CF-B996-47F883F196DFQ26863501-A9D3B4A7-1BB6-4410-8BAA-43E38F10F8AFQ26864870-7AE9B2A0-9349-46B0-B543-2C481E4340A9Q28078268-3EEEFC01-30E7-48B5-893C-892D5E7CBDC9Q28289090-C832BDC3-7C61-4CD3-88A9-7B2F3A4E6B22Q33983255-B4AF455E-CB20-44DF-84E8-49BB90432760Q34380368-C14C7798-0610-425A-B62E-EA51BD4FAE0CQ34715598-B5A89325-45A8-4944-98B5-EBD032D0573EQ35048469-23EDBCCB-2913-4BA1-83B5-68E9AE3DBAA4Q35073758-B0AA6BF1-943F-4940-9B76-E17E813DFB58Q35201518-8CDD5CC2-7136-4107-A6EE-427E548CE142Q35740025-FA067F1B-659D-4562-B919-80D86E1E0322Q35800291-A2137019-00EB-43EB-818E-454CDEEC7E45Q36075291-AA8115F1-FBFC-4487-A3C5-1A204F52AEE0Q36255484-B9E3D388-B04A-4496-86FC-F5640DD11C0BQ36413964-616B7B8C-27B7-45C7-B8F4-1901DC3AC48CQ36437713-A6D096A8-8200-4C75-885B-BE9274B89C95Q36546469-42F77438-4C21-47DF-9F21-A3D5A7040EA5Q36738836-0CE9EA23-BEB5-4705-885F-712EA4E22D7EQ36771796-985D8513-AB01-4D6A-AB44-AC43BF58832EQ37579567-5C7666E5-77C4-42E8-90B9-A5F515ECA34CQ37634102-0D35A019-4F1F-4C27-B0BE-DF633837B6EAQ37676283-17F7F021-F631-49E8-B596-BE6F4E3AA862Q37693690-679BE524-013C-4F49-B51D-B7BAD6389578Q38268221-6EA0FD3E-F149-40B0-88B5-6CA76297EF5FQ38785380-8714C7EE-C247-45DE-A908-20B524A5778BQ38817102-0A76BCC5-B63B-48EA-A85A-3BBAE7B96CE1Q39044559-2B831277-2749-44EF-951F-7A25D5C60C6AQ39076159-11A7BC3B-21F7-4DF0-8894-6BDC2EA267C5Q39175665-DCB2B048-B76C-431C-ACF0-C917DE60CF88Q39540757-E1F81A7E-5944-4492-9EE0-08899ED9DCD7Q39643726-96F59874-F707-44E2-8760-F30ACDA509ADQ41470356-7A5385B7-F227-43D5-963D-4806BEB35817Q41838038-AE826A7D-7901-41CA-BB7A-24F919E25DC3Q44601913-80A7F3DD-A85B-4144-BAE4-39123C7ABA93Q46237274-5830B19C-C865-4AD0-8A3A-8B8E2E0679C2Q47622968-77DB7184-E0B3-4AFB-9094-487450AED67FQ47687840-031DB6C3-24BC-4499-B937-C455E78BE2C7Q47730914-BBBDBAA6-1BF8-4944-ACF5-035437DF2AB9
P2860
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase I and pharmacologic tria ...... in refractory acute leukemias.
@ast
Phase I and pharmacologic tria ...... in refractory acute leukemias.
@en
type
label
Phase I and pharmacologic tria ...... in refractory acute leukemias.
@ast
Phase I and pharmacologic tria ...... in refractory acute leukemias.
@en
prefLabel
Phase I and pharmacologic tria ...... in refractory acute leukemias.
@ast
Phase I and pharmacologic tria ...... in refractory acute leukemias.
@en
P2093
P2860
P1476
Phase I and pharmacologic tria ...... in refractory acute leukemias
@en
P2093
B Douglas Smith
Brian M Thomas
Christopher Sorge
David A Parry
Douglas E Gladstone
Hetty E Carraway
Jacqueline M Greer
Jo Ann Horowitz
Judith E Karp
Karen Mackey
P2860
P304
P356
10.1158/1078-0432.CCR-12-2442
P407
P577
2012-10-23T00:00:00Z